Xylem Inc. $XYL Shares Bought by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans grew its position in Xylem Inc. (NYSE:XYL) by 378.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 47,670 shares of the industrial products company’s stock after purchasing an additional 37,701 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Xylem were worth $6,166,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Pathway Financial Advisers LLC increased its position in Xylem by 12.0% during the 2nd quarter. Pathway Financial Advisers LLC now owns 6,379 shares of the industrial products company’s stock valued at $825,000 after buying an additional 685 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Xylem during the second quarter worth about $294,000. Advisory Services Network LLC increased its holdings in shares of Xylem by 31.2% during the second quarter. Advisory Services Network LLC now owns 3,925 shares of the industrial products company’s stock valued at $508,000 after acquiring an additional 934 shares in the last quarter. State of Wyoming purchased a new position in shares of Xylem in the 2nd quarter valued at approximately $89,000. Finally, Pitcairn Co. grew its position in Xylem by 12.8% during the 2nd quarter. Pitcairn Co. now owns 6,059 shares of the industrial products company’s stock worth $784,000 after purchasing an additional 689 shares during the last quarter. Hedge funds and other institutional investors own 87.96% of the company’s stock.

Xylem Stock Performance

NYSE XYL opened at $138.04 on Friday. The firm has a market capitalization of $33.61 billion, a P/E ratio of 35.49, a PEG ratio of 2.12 and a beta of 1.18. The stock has a 50-day simple moving average of $143.90 and a two-hundred day simple moving average of $139.36. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.50 and a current ratio of 1.96. Xylem Inc. has a fifty-two week low of $100.47 and a fifty-two week high of $154.27.

Xylem (NYSE:XYL) last posted its earnings results on Tuesday, October 28th. The industrial products company reported $1.37 EPS for the quarter, topping the consensus estimate of $1.23 by $0.14. The firm had revenue of $2.27 billion for the quarter, compared to analyst estimates of $2.22 billion. Xylem had a return on equity of 10.77% and a net margin of 10.66%.Xylem’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the company earned $1.11 earnings per share. Xylem has set its FY 2025 guidance at 5.030-5.080 EPS. On average, equities analysts forecast that Xylem Inc. will post 4.65 earnings per share for the current year.

Xylem Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 23rd. Shareholders of record on Tuesday, November 25th will be given a $0.40 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 1.2%. Xylem’s dividend payout ratio is 41.13%.

Analysts Set New Price Targets

A number of research analysts have issued reports on XYL shares. Barclays raised their price target on shares of Xylem from $165.00 to $172.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Citigroup raised their target price on Xylem from $173.00 to $182.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. TD Cowen boosted their price target on Xylem from $130.00 to $135.00 and gave the company a “hold” rating in a research note on Friday, December 5th. Mizuho set a $160.00 price objective on Xylem in a report on Wednesday, October 29th. Finally, UBS Group lifted their target price on Xylem from $168.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $167.40.

Insider Activity

In other news, EVP Claudia S. Toussaint sold 10,421 shares of the firm’s stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $152.64, for a total transaction of $1,590,661.44. Following the sale, the executive vice president directly owned 31,250 shares in the company, valued at $4,770,000. This trade represents a 25.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Victoria D. Harker sold 1,700 shares of the company’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $148.14, for a total value of $251,838.00. Following the completion of the transaction, the director directly owned 16,875 shares of the company’s stock, valued at $2,499,862.50. The trade was a 9.15% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.27% of the company’s stock.

Xylem Company Profile

Xylem Inc (NYSE: XYL) is a global water technology company that designs, manufactures and services engineered systems and equipment for the transport, treatment, testing and efficient use of water. Its product portfolio spans pumps and pumping systems, valves, filtration and disinfection equipment, sensors and analytical instruments, and digital solutions for monitoring and control of water infrastructure. Xylem serves the full water cycle with offerings for water and wastewater utilities, industrial customers, commercial and residential buildings, and agricultural applications.

The company was established as an independent publicly traded company in 2011 following a corporate spin-off from ITT Corporation and is headquartered in Rye Brook, New York.